Bio-Techne Corporation
TECH$72.29
+$0.39 (0.54%)+0.54%
ClosedLoading chart...
IndexN/A
Market Cap11.32B
Enterprise Value8.39B
Income$0.07B
Sales$1.22B
Employees3,100
P/E37.26
P/S6.64
P/B4.22
P/C31.59
EV/EBITDA38.67
EV/Sales26.03
EPS (ttm)1.94
Earnings2025-11-05
Gross Margin64.80%
Oper. Margin8.38%
Profit Margin6.02%
Volume2.99M
Shs Outstand0.16B
Change0.54%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTD15.12%
Perf Year-9.44%
Perf 3Y-15.06%
Perf 5Y-21.92%
Perf 10Y234.32%
IPO1989-02-09
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M | $714.01M | $642.99M |
| Cost of Revenue | $429.36M | $389.33M | $366.89M | $349.10M | $298.18M | $255.50M | $240.51M | $210.85M |
| Gross Profit | $790.27M | $769.73M | $769.82M | $756.50M | $632.85M | $483.19M | $473.49M | $432.14M |
| Gross Margin | 64.80% | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% |
| Operating Expenses | $688.02M | $563.04M | $470.87M | $459.91M | $395.55M | $325.77M | $347.91M | $295.96M |
| Operating Income | $102.25M | $206.69M | $298.94M | $296.59M | $237.30M | $157.42M | $125.58M | $136.18M |
| Operating Margin | 8.38% | 17.83% | 26.30% | 26.83% | 25.49% | 21.31% | 17.59% | 21.18% |
| Net Income | $73.40M | $168.10M | $285.26M | $272.05M | $140.41M | $229.30M | $96.07M | $125.35M |
| Net Margin | 6.02% | 14.50% | 25.10% | 24.61% | 15.08% | 31.04% | 13.46% | 19.49% |
| EPS (Basic) | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 | $0.64 | $0.84 |
| EBITDA | $216.88M | $313.14M | $457.11M | $413.76M | $249.87M | $378.41M | $211.89M | $200.60M |
| Stock Option Compensation Expense | $40.83M | $38.04M | $39.23M | $42.18M | $48.98M | $32.37M | $32.28M | $28.24M |
| Price To Earnings Ratio | 110.41 | 67.18 | 44.98 | 49.97 | 124.26 | 44.00 | 82.30 | 44.24 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | $8.10B | $11.29B | $12.83B | $13.59B | $17.45B | $10.09B | $7.91B | $5.54B |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B | $1.88B | $1.59B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $639.06M | $635.02M | $672.18M | $593.79M | $691.72M | $646.40M | $718.82M | $514.06M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $1.92B | $2.07B | $1.97B | $1.70B | $1.56B | $1.38B | $1.17B | $1.08B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $1.92B | $2.07B | $1.97B | $1.70B | $1.56B | $1.38B | $1.17B | $1.08B |
| Total Liabilities & Stockholders Equity | $2.56B | $2.70B | $2.64B | $2.29B | $2.26B | $2.03B | $1.88B | $1.59B |
| Book Value Per Share | $12.18 | $13.12 | $12.51 | $10.84 | $10.14 | $9.04 | $7.71 | $7.20 |
| Tangible Book Value Per Share | $3.63 | $3.74 | $3.56 | $2.21 | $0.72 | $0.89 | $-0.97 | $0.23 |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 2.87% | 6.22% | 10.81% | 11.86% | 6.20% | 11.31% | 5.10% | 7.87% |
| Return on Equity | 3.83% | 8.13% | 14.51% | 15.99% | 8.98% | 16.60% | 8.24% | 11.62% |
| Return on Invested Capital | 3.18% | 7.32% | 9.99% | 12.08% | 10.47% | 6.72% | 6.00% | 8.99% |
| Quick Ratio | 2.38 | 2.75 | 3.50 | 2.64 | 2.59 | 3.92 | 3.15 | 3.97 |
| Current Ratio | 3.46 | 3.87 | 4.84 | 3.44 | 3.35 | 4.88 | 4.05 | 5.06 |
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $73.40M | $168.10M | $285.26M | $272.05M | $140.41M | $229.30M | $96.07M | $125.35M |
| Depreciation | $109.90M | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M | $78.17M | $64.46M |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $287.56M | $298.98M | $254.39M | $325.27M | $352.16M | $205.22M | $181.62M | $170.37M |
| Capital Expenditures | $31.01M | $62.88M | $38.24M | $44.91M | $44.30M | $51.74M | $25.41M | $20.93M |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | $50.39M | $50.42M | $50.28M | $50.19M | $49.62M | $48.90M | $48.36M | $47.97M |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | $275.73M | $80.04M | $19.56M | $160.95M | $43.18M | $50.11M | $15.40M | $0.00 |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $256.55M | $236.10M | $216.15M | $280.36M | $307.86M | $153.47M | $156.21M | $149.43M |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
JAZZ vs. TECH: Which Stock Is the Better Value Option?zacks.com California State Teachers Retirement System Grows Holdings in Bio-Techne Corp $TECHdefenseworld.net CMB.TECH fleet updateglobenewswire.com Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH?fool.com Madison Mid Cap Fund Q2 2026 Portfolio Activityseekingalpha.com Conestoga SMid Cap Composite Q2 2026 Portfolio Reviewseekingalpha.com Bank of Nova Scotia Sells 38,334 Shares of Bio-Techne Corp $TECHdefenseworld.net Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?zacks.com
Show 12 more stories
Dimensional Fund Advisors LP Boosts Holdings in Bio-Techne Corp $TECHdefenseworld.net INTURAI FAST TRACKS DOMECOMMAND COMMERCIALISATION WITH EUROPEAN DEFENCE TECH HUB AND SINGAPORE AIR FORCEprnewswire.com American Capital Management Inc. Boosts Stock Holdings in Bio-Techne Corp $TECHdefenseworld.net Bio-Techne Corp $TECH Holdings Lowered by Bessemer Group Inc.defenseworld.net IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?fool.com Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolioprnewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)globenewswire.com Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholdersglobenewswire.com Shareholder Alert: Ademi LLP investigates whether Bio-Techne Corporation is obtaining a Fair Price for Public Shareholdersglobenewswire.com BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)globenewswire.com Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECHbusinesswire.com Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?gurufocus.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Kelderman Kim
F
2.3K
$62.57
$144K
Nov 3, 25
Company
About the company
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Discover more
You may be interested in